Our Approach
Current Therapies
25 million people in the US – including 14M women – have mild to moderate anemia. These patients require 20 to 100 mgs/month of iron. While diet can help improve iron levels, in most cases, an additional therapy is needed to bring iron levels to acceptable levels. Oral iron therapy is the current standard of care, yet nearly half of patients have mild to severe gastro intestinal side effects including constipation, nausea, and diarrhea. As a result, many patients do not comply with their therapy and therefore are not receiving sufficient levels of iron. Fe3 is targeting the millions of patients who cannot tolerate oral iron, and also are not candidates for IV iron.
Fe3, has developed a novel treatment for iron-deficiency anemia, a disorder which affects more than 14M women in the US alone. The most common treatment for these women is an oral iron supplement; however, nearly half of these patients cannot tolerate oral iron due to nausea, constipation and other gastrointestinal adverse effects.
We have developed a disposable transdermal patch that requires minimal preparation and is gentle on the skin. Worn overnight once a week, the Fe3 patch delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects. As a result, our therapy has the potential to significantly improve the patient experience and increase patient compliance.
We have significant pre-clinical and market research data and are planning for clinical trials.